about
The promise and perils of 'targeted therapy' of advanced ovarian cancerPathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancerOptimal chemotherapy treatment for women with recurrent ovarian cancerToxicities of the platinum antineoplastic agents.Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.An Example of Ovarian Cancer as a 'Chronic Disease Process' - 11-Year Survival with Multiple Treatments for Recurrent and Progressive DiseasePicking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian CancerCombination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series.Playing the waiting game ... the asymptomatic patient with recurrent ovarian cancer detected only by rising Ca125 levels.Cell fate regulation by gelsolin in human gynecologic cancers.Radioimmunoscintigraphy in patients with ovarian cancer.Role of chemotherapy in the management of ovarian cancer.Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancerAntiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literatureClostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancersWeekly paclitaxel infusion as salvage therapy in ovarian cancer.Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model.Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.Doublet chemotherapy in the elderly patient with ovarian cancer.Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancerPromoter hypermethylation of FANCF and outcome in advanced ovarian cancer.Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy.HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cellsIn vitro chemoresponse in metachronous pairs of gyneclologic cancersHormone response in ovarian cancer: time to reconsider as a clinical target?NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo.Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer ModelsEffects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.The changing landscape of therapeutic strategies for recurrent ovarian cancer.Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
P2860
Q28282889-8048297B-C852-4A41-A660-AB70A46288B2Q28538059-CD15C6CA-58B8-41C7-8B28-F7CD858F50DEQ33302771-97A035F4-0099-4095-BFEC-B87009517153Q33357351-0AE15891-1502-4C1F-906C-E53D04BC2620Q33365034-5F9FA9C7-070E-4AE4-8F03-D6D5F5DB2F78Q33371474-FCFE51BB-5DE0-4701-8F9E-E1C60417CEBEQ33409343-F6CAD151-406E-4B7B-BAF8-ACF545C1F3A4Q33415076-47220B3F-E688-4718-9E21-ED6F819BA3C0Q33612533-4C658CDD-E1C1-47CC-9745-1F0D07770A76Q33756409-7AF6BC58-6631-45D8-894E-EFBF46464260Q33858199-1E5F4E0E-8CE8-4C2A-BFD6-942B50012AA8Q34334561-90778F21-3E95-408B-83C4-5E644A50303CQ34407454-2BB1A300-F0E1-49D0-B719-D37AB3FA0320Q34415800-380BB859-4A5E-43A4-8090-EA275C0BD23FQ34734126-E1979992-C9B6-4F12-A82A-E0385DE56B94Q35114915-8FA0D3BF-72AB-424D-B481-DE08FB0337B5Q35138497-025825E0-63EF-47B8-83F4-1EC62792E833Q35564030-D99CD92D-ADEE-4E5E-9B3F-AA5113E1B0F9Q35589197-8009A89C-C96F-4584-9A5F-F631853270BDQ35684285-D715AB92-C2E4-4405-9948-A1DED862DF49Q36029756-302B37DC-D6BF-4AA1-9D1A-F62D526BFF5EQ36093220-103E614D-54A6-4B63-8BEA-231E14D089F9Q36405668-5BC723FE-4863-417E-B426-9FD89A6BE909Q36530680-2296333B-D1EB-4A07-B2B1-3302F5DA4507Q36610752-9528EBB2-C896-4CA0-8BB2-43B8D99C5157Q36615338-3E963B8C-E30D-4019-85FC-A0719A46116BQ36615636-F41FCB39-3192-4738-A062-A394F1C038F5Q36661444-F1A04D99-3084-450B-B2EB-A61FB68313ABQ36907257-D6464A1C-A980-4108-B802-3AA0C96CCB15Q36937532-A274F690-4F30-403C-842A-24BF8C2D3367Q36966197-8F2DCB6F-3120-4021-A3B7-09C628034121Q37272785-765D507F-0108-4CD7-92B8-D7D6D67B5494Q37284717-299EE3F9-4792-42F4-B3DE-E46FA15BA4D0Q37447340-B9B60578-12AC-4B10-B5CC-00CADFB0F8C4Q37530604-DB4822B2-9DD4-4E9F-AF92-15BCF12ADF2AQ37631697-3375AE39-7A14-450E-9CAD-AA5383780D86Q37696327-2AC5FAA2-EA31-46A7-97DE-6394E4BA6B0BQ37765581-C1F1248D-1FF0-49B3-840D-A79848DD457EQ38048887-54FE7616-7897-4500-99DC-ADDCEA5BB946Q38376696-A633A3DF-DF74-4DDF-A509-61DC97358D11
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Second-line treatment of ovarian cancer.
@ast
Second-line treatment of ovarian cancer.
@en
type
label
Second-line treatment of ovarian cancer.
@ast
Second-line treatment of ovarian cancer.
@en
prefLabel
Second-line treatment of ovarian cancer.
@ast
Second-line treatment of ovarian cancer.
@en
P1433
P1476
Second-line treatment of ovarian cancer.
@en
P2093
P356
10.1634/THEONCOLOGIST.5-1-26
P577
2000-01-01T00:00:00Z